You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》和黃醫藥(00013.HK)今日起本港招股 入場費22,727元
長和(00001.HK)旗下生物醫藥公司和黃醫藥(00013.HK)(HCM.US)公開招股詳情,計劃發售1.04億股股份,當中12.5%在港公開發售,餘下87.5%爲國際配售。每股最高發售價45元,每手500股,入場費爲22,726.74元;由今日(18日)起至下週三(23日)中午公開招股,預計於6月30日上市。摩根士丹利、Jefferies及中金爲聯席保薦人。

是次招股引入5名基石投資者,包括CA Fern Parent、CPP Investments、泛大西洋投資集團、HBM Healthcare Investments及中金啓融基金等,合共認購3.25億美元股份。

公司預計,若根據指示性最高發售價45元,全球發售所得款項淨額將約爲44.41億元,當中50%用於推進賽沃替尼、索凡替尼、(口夫)(口奎)替尼、HMPL-689及HMPL-523的後期臨牀計劃以進行註冊試驗及潛在提交NDA申請;10%將用於支持進一步的概念驗證研究,並資助內部研究以持續擴大的癌症及免疫疾病產品組合;20%將用於進一步增強集團在商業化、臨牀、監管及生產方面的綜合實力;15%將爲潛在的全球業務發展及策略收購機會提供資金;餘下5%將用作營運資金、在全球及中國擴大內部能力以及一般企業用途的資金。

和黃醫藥指其美國預託證券(每份代表五股股份)於納斯達克上市買賣,於2021年6月15日美國預託證券於納斯達克的最後銷售報價爲每份美國預託證券29.73美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account